Canada Markets close in 13 mins

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.820.00 (0.00%)
As of 10:29AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close5.82
Open5.82
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.82 - 5.82
52 Week Range5.82 - 11.25
Volume500
Avg. Volume2
Market Cap146.124M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Poxel Announces Financial Calendar for 2022

    LYON, France, January 04, 2022--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its calendar for the publication of financial information for 2022.

  • Business Wire

    Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022

    LYON, France, December 14, 2021--POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in January 2022.

  • Business Wire

    Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases

    LYON, France, December 06, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel's X-linked adrenoleukodystrophy (ALD) program.